dr. lenz on the safety profile of checkmate-142 trial in crc
Published 4 years ago • 56 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
1:14
dr. lenz on updated results of the checkmate-142 trial in mcrc
-
1:54
dr. lenz on updated data from checkmate 142 with nivolumab ipilimumab in mcrc
-
1:13
dr. lenz on breakthrough designation of encorafenib, binimetinib, and cetuximab in braf crc
-
2:32
dr. overman discusses updated findings of checkmate-142 in patients with msi-h mcrc
-
4:31
checkmate142: checkpoint combination therapy in first-line colorectal cancer
-
1:00
dr. lenz on next steps with immunotherapy in mcrc
-
2:04
dr. lenz on the changing landscape of metastatic colorectal cancer
-
2:45
dr bazhenova on updated data from the trust-i trial of taletrectinib in ros1 nsclc
-
6:19
should you treat melanoma with nivolumab and relatlimab (opdualag)?
-
5:14
nlrp3 inhibitors for tumor-driven inflammatory colitis
-
1:24:27
the renal pathology of check point inhibitors
-
1:11
nivolumab/ipilimumab combination data promising in msi-h/dmmr mcrc
-
1:31
dr. michael j. overman on immunotherapy in colorectal cancer
-
4:58
tas-102 in refractory metastatic colorectal cancer
-
14:05
checkmate-77t: perioperative nivolumab benefit for nsclc
-
0:50
checkmate 650: nivolumab ipilimumab, ipilimumab alone, or cabazitaxel in mcrpc
-
9:54
idea trial: 3 vs 6 months of adjuvant therapy in crc
-
1:50
dr lynce on ongoing trials evaluating novel combinations in inflammatory breast cancer
-
1:33
checkmate 920: nivolumab plus ipilimumab for renal cell cancer
-
4:47
checkmate 227: combining ctla-4 and pd-l1 in nsclc
-
3:06
solti-1503 prometeo: t-vec atezolizumab in patients with residual bc after neoadjuvant chemo
-
2:56
keynote-010: pembrolizumab, anti-pd-1, for advanced nsclc with pd-l1 expression